Adiana Inc.
This article was originally published in Start Up
Executive Summary
Adiana aims to improve the most popular method of female sterilization--tubal ligation--with a device that can be used in a doctor's office, to perform the procedure less invasively. A catheter guided through the vagina on up into the fallopian tubes will give a short dose of radiofrequency to ablate the cells lining the tube, and a small spongy matrix will be left behind. The energy-induced injury will prompt tissue ingrowth into the matrix, so that healthy tissue will permanently block the tubes.
You may also be interested in...
Permanent Contraception
Given the huge impact that having a baby has on every aspect of a woman's life--and that of her mate--it's small wonder that a growing number of companies are aiming to offer Baby Boomers improved contraceptive choices. Some are developing devices to make the widely performed tubal ligation surgery, which renders women sterile, less invasive, more convenient and safer than it has been to date. At least one firm hopes to give men a chance to participate in family planning via reversible vasectomization.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.